[177] An analysis of events in the US FDA Adverse Event Reporting System suggests an association between several GLP-1 agonists (including semaglutide) and cutaneous reactions, such as dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and morbilliform drug eruptions
According to the FDA, litigation challenging these determinations is ongoing, and the agency has said it will exercise enforcement discretion given the large number of patients who may need to transition
This comprehensive GLP-1 probiotic supplement combines ingredients traditionally associated with prebiotics, probiotics, and postbiotics in one supplement
Another study determined that combining GLP-1 and estrogen activated estrogen receptors in GLP-1-targeted tissues with unprecedented efficacy in order to improve metabolic syndrome a cluster of conditions including high blood pressure, high cholesterol, and high blood sugar